More Study Participants Needed for HIV Cure Research (Video)
April 10, 2016
On behalf of IFARA, CARE community advisory board coordinator Jeff Taylor spoke with Paula Cannon, Ph.D., Karine Dubé and Warner Greene, M.D., Ph.D., about research into a cure for HIV. One potential avenue is gene therapy that would modify a person's own immune system either to make that person's cells immune to HIV or to prompt them to attack the virus. Similar strategies are being developed for cancer treatment, and researchers involved in either disease are "knocking on each other's doors," Greene said. Another path is a "shock and kill" strategy whereby toll-like receptor antagonists are used to trigger a person's innate immune system, then a novel vaccine is injected to kill the reactivated cells. However, it is difficult to find people willing to participate in such studies. CARE developed a curriculum to make cure research accessible to HIV-affected communities in order to improve enrollment in such trials. The organization will also be soliciting community feedback at this year's AIDS conference in Durban, South Africa, among other venues.
Watch the video to learn more:
The video above has been posted on TheBodyPRO.com with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the CROI 2016 conference, as well as earlier meetings.
Barbara Jungwirth is a freelance writer and translator based in New York.
Follow Barbara on Twitter: @reliabletran.
Copyright © 2016 Remedy Health Media, LLC. All rights reserved.
This article was provided by TheBodyPRO.com. It is a part of the publication The 23rd Conference on Retroviruses and Opportunistic Infections.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.